Xencor jumps 16% as its kidney cancer drug shrinks tumors in early trial
Why is Xencor stock up today?
Xencor's experimental drug XmAb819 shrank tumors in 5 of 11 patients (45.5%) with advanced kidney cancer at the dose it picked for late-stage trials, in people whose cancer had kept growing after at least two kinds of treatment. That rate was above the roughly 25% benchmark Truist had outlined before the data, and numerically higher than approved drugs achieved in separate trials. The results come from a small early trial without a comparison group, and how long responses last is still unknown.
- Move
- ▲ 15.9%
- Price
- $25.18 → $29.18
- Value gained
- ~$0.3B
- Chosen-dose response rate
- 45.5% (5 of 11)
- Truist benchmark
- ~25%
- Cash runway
- Into 2029
Prices: closing price, Oct 26, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean
Closing prices for Oct 23 and Oct 26, 2026, per Stock Analysis.
Snapshot at the Oct 26, 2026 close
- Market value
- $2.2B
- Enterprise value
- $1.8B
- Price/sales
- 20.7×
- EV/sales
- 17.0×
- P/E
- n/m
- Price/FCF
- n/m
- Revenue growth
- −29%
- FCF margin
- −198%
- Net cash
- $381M
Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Aug 5, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $29.18; 74.4 million shares (common shares on the cover page of the 10-Q filed Aug 5, 2026). n/m = not meaningful (e.g. negative earnings).
What happened
Xencor reported early results for its kidney cancer drug that exceeded a response benchmark one analyst had set before the data, and the stock touched its highest level since early 2023 during the day.
- On Sunday, Oct 25, Xencor presented updated Phase 1 results for XmAb819 at the ESMO cancer congress in Madrid. City of Hope’s Dr. Sumanta Pal gave the talk.
- XmAb819 is a “T-cell engager”. It latches onto ENPP3, a protein that Xencor says is plentiful on kidney cancer cells but scarce on normal tissue, and onto the patient’s own immune T cells, pulling the two together so the T cells attack the tumor.
- The trial enrolled people with advanced clear cell kidney cancer whose disease had kept growing after an immune treatment and a pill that blocks VEGF, a signal tumors use to grow new blood vessels. The typical patient had been through three earlier treatments.
- At 400 micrograms per kilogram of body weight, the dose Xencor chose for late-stage trials, tumors shrank in 5 of 11 patients (45.5%). In later follow-up through Oct 1, a sixth response was awaiting confirmation, and an estimated 82% were alive without their cancer worsening at six months, according to the company.
- Xencor said it will discuss a faster (accelerated) approval path with the FDA in the first half of 2027 and plans a randomized trial against tivozanib, an approved kidney cancer pill.
- The stock closed up 15.9% at $29.18 on Monday, after rising roughly 33% during the day. That added about $0.3 billion in market value. The S&P 500 (+0.7%), the Nasdaq Composite (+0.8%) and the XBI biotech fund (+0.6%) rose far less.
The results, in context
At its two higher doses, XmAb819’s response rate was numerically about twice what approved later-line drugs reached in their own, separate trials; Xencor itself warns that such comparisons are “for illustration only”.
A “confirmed response” here is a partial or complete response under the standard RECIST 1.1 rules: the combined size of the measured tumors fell by at least 30% (or they disappeared), a scan at least four weeks later confirmed it, and the disease did not progress elsewhere. It measures tumor shrinkage, not how long it lasts or whether patients live longer.
| Treatment (trial) | Patients | Confirmed response rate |
|---|---|---|
| XmAb819, 400 mcg/kg (Phase 1) | 11 | 45.5% |
| XmAb819, 200 mcg/kg (Phase 1) | 25 | 44% |
| XmAb819, 100 mcg/kg (Phase 1) | 30 | 30% |
| Belzutifan (Phase 3, LITESPARK-005) | 374 | 21.9% |
| Tivozanib (TiNivo-2 subgroup) | Not stated | 10.5% |
Sources: Xencor (XmAb819, tivozanib); NEJM (belzutifan). The trials enrolled different patients and used different designs, so the table is a reference, not a head-to-head result.
- Merck’s belzutifan (Welireg) shrank tumors in 21.9% of patients previously treated with immunotherapy and blood-vessel-blocking drugs in its Phase 3 trial, NEJM reported. Xencor’s presentation puts approved later-line options at roughly 17–23%.
- Across the three expansion doses, Xencor reported responses in 8 of 23 patients (35%) who had already received a drug in belzutifan’s class.
Why the market reacted this way
The reported response rate exceeded a benchmark Truist had outlined before the results. No analyst or company statement found so far explains the size of the move.
- Investing.com reported on Sept 28 that Truist considered a roughly 25% response rate, a median of more than six months without the cancer worsening, and manageable cytokine release syndrome (an inflammatory immune reaction) enough to support a Phase 3 trial. The response rate at the chosen dose was above that benchmark. The median time without worsening has not been reached yet, so that condition cannot be judged.
- Responses rose with the dose (30%, 44%, 45.5%), Xencor noted, and 19 of the 25 responses across all doses were still ongoing at the Sept 1 data cutoff.
- Across 68 patients in the expansion groups, Xencor reported grade 3 or higher treatment-related side effects in 72.1%, mostly liver-enzyme rises and rash during the first four weeks. Cytokine release syndrome of grade 3 or higher occurred in 5.9%. Separately, 5.9% stopped treatment because of treatment-related side effects.
- Xencor plans to discuss a faster approval path with the FDA and is enrolling patients earlier in treatment and with other ENPP3-carrying cancers (papillary kidney, lung, colorectal). It projects that its cash will last into 2029 under its current operating plans.
Does this change Xencor’s future?
What did NOT change
- The data are early. The headline rate rests on 11 patients, and with so few the true rate could plausibly be anywhere from about 17% to 77% (the company’s 95% confidence range). Responses were judged by trial doctors, not an independent panel, and there was no comparison group.
- How long responses last is unknown. Median follow-up at the chosen dose was six months.
- XmAb819 is experimental, and Xencor has not announced an approval date. Treatment starts with weekly “priming” doses that build up to the full dose, and Xencor plans new groups testing dosing every three weeks and less time in hospital.
What DID change
- XmAb819 now has a proposed late-stage dose, a planned discussion with the FDA and a response rate that, in early data, is numerically higher than those reported for approved later-line drugs in separate trials.
Our read
The results support further testing of XmAb819. Larger patient groups and longer follow-up are needed to judge its potential; the first test is whether the response rate holds in at least 20 patients at the chosen dose in the first half of 2027.
What to watch next
- 1H 2027
- Results from at least 20 patients at the chosen dose, up from 11 now, which will show whether the response rate holds.
- 1H 2027
- Talks with the FDA about a faster (accelerated) approval in patients who have run out of standard options, and first results from an under-the-skin version.
- By end of 2027
- Start of a randomized trial against tivozanib, an approved kidney cancer pill, which Xencor says could support full approval.
Quick questions
What does a 45.5% confirmed response rate mean?
In 5 of 11 patients, the combined size of the measured tumors fell by at least 30%, and a scan at least four weeks later confirmed it. It measures tumor shrinkage, not how long it lasts or whether patients live longer.
Is XmAb819 approved?
No. It is in a Phase 1 trial. Xencor plans to discuss a faster approval path with the FDA in the first half of 2027 and to start a randomized trial by the end of 2027.
How does it compare with existing kidney cancer drugs?
Xencor's presentation puts response rates for approved later-line drugs at roughly 17–23% in their own trials (belzutifan: 21.9% in its Phase 3 trial, NEJM). XmAb819's rate is numerically higher, but the trials enrolled different patients, so this does not show it works better.
What does Xencor say about its funding?
Xencor projects that its cash will fund operations into 2029 under its current operating plans.
Updates
- : Corrected the valuation snapshot: market value now uses common shares outstanding (74.4 million on the 10-Q cover page, Jul 31, 2026), our standard basis, instead of 76.0 million shares including pre-funded warrants; market value $2.2B (was $2.2B), with enterprise value and multiples recalculated. Prices and dates unchanged.
- : Corrected the valuation snapshot: cash and investments now include short-term marketable securities ($486 million, previously $153 million); net cash ($381 million, previously $48 million), enterprise value ($1.84 billion, previously $2.17 billion) and EV/sales (17.5×, previously 20.7×) updated. Prices and dates unchanged.
About Xencor: Website (external site)Investor relations (external site)SEC filings (external site)
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.